Nf Kappa B Inhibitors Pipeline Insight
DelveInsight’s, “NF-Kappa B Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in NF-Kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
NF-Kappa B Inhibitors Understanding
NF-Kappa B Inhibitors: Overview
NF-kappa B, are Nuclear Factor kappa light chain enhancer of activated B cells, comprises a family of inducible transcription factors. NF-kB is a short name of Nuclear Factor kappa-light-chain-enhancer of activated B cells. NF-kB molecular are usually dimers. A typical structure of NF-kB is the P50-P65 dimer (NF-kB1/RelA).
Function - NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumor genesis, and apoptosis. NF-kappa-B regulates DNA transcription, cytokine production, cell survival, and other important cell events, especially play a key role in regulating the immune response to infection.
NF-Kappa B Inhibitors - Abnormal NF-kB signaling results in human diseases, such as immune disorders, inflammation, and various cancers. An aberrant NF-kappaB activation is associated with cancer development and contributes to the pathogenesis of chronic inflammatory diseases like rheumatoid arthritis (RA) and multiple sclerosis (MS). NF-κB signaling pathway provides a desirable target for therapeutic development. These inhibitors include various natural products, chemicals, metals, metabolites, synthetic compounds, peptides, proteins (cellular, viral, bacterial, fungal), and physical conditions.
The companies and academics are working to assess challenges and seek opportunities that could influence NF-Kappa B Inhibitors R&D. The therapies under development are focused on novel approaches for NF-Kappa B Inhibitors.
NF-Kappa B Inhibitors Emerging Drugs Chapters
This segment of the NF-Kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NF-Kappa B Inhibitors Emerging Drugs
MK-7110 (formerly CD24Fc) is a potentially first-in-class recombinant fusion protein that targets the innate immune system. It is in Phase III clinical trials for the prophylactic treatment of graft-versus-host disease (GVHD) that preserves or enhances the graft-versus-leukemia (GVL) effect in patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). MK-7110 comprises the nonpolymorphic regions of CD24 attached to the Fc region of human IgG1. The company has received Orphan Drug designation for CD24Fc in the US and Europe.
NE3107 – an orally bioavailable, small molecule produced by chemical synthesis – was initially discovered by Hollis-Eden Pharmaceuticals and selected for clinical development to treat inflammatory diseases in humans in 2006 under the product code HE3286. Currently, NeurMedix is developing NE3107 as a therapeutic for neurological disorders in which neuroinflammation is a major contributing factor.
AMG 0101 (NF-κB Decoy Oligodeoxynucleotide): AnGes
NF-κB Decoy Oligodeoxynucleotide is a decoy oligo with the same genetic sequence as the NF-κB-binding site. As it targets the transcription factor itself, it is expected to have superior efficacy and milder side effects than conventional drugs due to its specificity and definite effects on the molecular target. AnGes is developing therapeutic agents based on its properties to treat patients suffering from atopic dermatitis, rheumatic arthritis, and restenosis – conditions caused by the excessive immunological response. It is currently in Phase III stage of development for Atopic dermatitis and Phase I for Chronic discogenic lumber back pain.
CXA-10 is an oral nitrated fatty acid (NFA) that impacts the fibrotic and inflammatory pathways. The drug acts through key reparative, metabolic and inflammatory pathways, including upregulation of the Nrf2 pathway and inhibition of nuclear factor-kappa B. In addition, it increases the expression of heat shock proteins, which act as chaperones during cellular stress. In six Phase I clinical trials, CXA-10 demonstrated target engagement and was shown to be tolerable and safe in more than 100 subjects. Importantly, it has shown an impact on relevant biomarkers of pharmacological action as well as inhibition of crucial biomarkers of disease-related inflammation and fibrosis.
Imx-110: Immix Biopharma
Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. It contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest if needed. Imx-110 has shown preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models – with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone and a wholesale shift in the tumor microenvironment post-administration.
Further product details are provided in the report……..
NF-Kappa B Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different NF-Kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on NF-Kappa B Inhibitors
There are approx. 10+ key companies which are developing the NF-Kappa B Inhibitors. The companies which have their NF-Kappa B Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Merck.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
NF-Kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Gene Therapies
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
NF-Kappa B Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NF-Kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-Kappa B Inhibitors drugs.
NF-Kappa B Inhibitors Report Insights
- NF-Kappa B Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
NF-Kappa B Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing NF-Kappa B Inhibitors drugs?
- How many NF-Kappa B Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for NF-Kappa B Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NF-Kappa B Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for NF-Kappa B Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?